Ilumya (also known by its generic name tildrakizumab-asmn) is a biologic medication that was approved by the FDA in March 2018 for the treatment of moderate-to-severe plaque psoriasis in adults. In October 2026, it was approved for the treatment of active psoriatic arthritis.
For moderate-to-severe plaque psoriasis, Ilumya is given by injection under the skin at weeks 0, 4, and every 12 weeks thereafter.
Ilumya is the first biologic treatment to earn the National Psoriasis Foundation (NPF) Seal of Recognition. The NPF Seal of Recognition highlights products that are meant to be safe and non-irritating for people living with psoriatic disease.
To learn more, please visit the Ilumya website.
